Intec Pharma names R Michael Gendreau as chief medical officer

JERUSALEM: Intec Pharma Ltd., a clinical-stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion Pill™ platform technology, announced it has named R. Michael Gendreau, M.D., Ph.D. to the position of Chief Medical Officer.

Dr. Gendreau, a seasoned industry veteran, brings to Intec Pharma over 30 years of experience in the drug development and pharmaceutical industry.

Michael added, "I am excited to join the Intec team. I look forward to contributing to the clinical development of the Accordion Pill technology platform and the completion of our Phase 3 AP-CD/LD program to bring this potentially game-changing therapy to Parkinson's patients around the world."

Dr. Gendreau joins Intec after having founded a consulting firm providing strategic advice on the design and management of clinical programs, strategic planning, and technology assessments for emerging pharmaceutical, diagnostic, and medical device companies.

He has served on various scientific advisory boards, executive strategic planning boards, and Data Safety Monitoring Boards. Prior to his consulting career, Dr. Gendreau served as Chief Medical Officer at Cypress Bioscience, Inc., a clinical-stage biotech company developing therapies for central nervous system disorders.

Additionally, he has served as Chief Medical Officer at other institutions including Battelle Memorial Institute. Dr. Gendreau received his B.S. in Chemistry from Ohio University and earned his M.D./Ph.D. from The Ohio State University.